CRI
Carter's, Inc.
CRI has the edge over GME overall, supported by stronger modeled upside and lower modeled downside.
GME
GameStop Corp.
GME trails on the overall score without a compensating advantage in the available component scores.
CRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CRI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
GME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Unavailable |
GME's profitability and cash flow are currently strong, and its revenue is stable. There isn't enough data to rate its balance sheet.
CRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.6x | $33.87 | — |
| Cheap | 8.6x | $51.89 | +53% |
| Forward | 10x | $33.87 | — |
| Fair | 12x | $74.79 | +121% |
| Expensive | 18x | $107 | +215% |
Historical ranges are pointers, not guarantees.
CRI has the edge over GME in the historical PE scenario, which offers more potential upside but is not a forecast.
GME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.62 | — |
| Cheap | 18x | $27.96 | +9.1% |
| Forward | 38x | $25.62 | — |
| Fair | 43x | $66.84 | +161% |
| Expensive | 252x | $388 | +1414% |
Historical ranges are pointers, not guarantees.
GME's PE is in its cheap range at 17x. Analysts expect earnings to fall, which would put today's price at 38x next year's earnings, in its fair range.
CRI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
CRI has the edge over GME on the outlook, with more favorable earnings and revenue expectations.
GME Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect GME's earnings and revenue to decline, with profitability weakening.
CRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.24 | -46% |
| Q3 2026 | $6.03 | +145% |
| Q2 2026 | $5.35 | +42% |
| Q1 2026 | $2.49 | -45% |
| Q4 2025 | $2.53 | -51% |
| Q3 2025 | $2.46 | -61% |
| Q2 2025 | $3.76 | -42% |
| Q1 2025 | $4.51 | -29% |
| Q4 2024 | $5.12 | -18% |
CRI earned $6.03 per share over the past year, up 145% from the year before.
GME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -56% |
| Q3 2026 | $1.54 | +93% |
| Q2 2026 | $1.34 | +153% |
| Q1 2026 | $0.77 | +133% |
| Q4 2025 | $0.89 | +394% |
| Q3 2025 | $0.80 | +515% |
| Q2 2025 | $0.53 | +563% |
| Q1 2025 | $0.33 | +1550% |
| Q4 2024 | $0.18 | +$0.21 |
GME has the edge over CRI on earnings, with more consistent year-over-year improvement.
CRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $752.5M | -0.7% |
| Q2 2026 | $615.5M | +5.2% |
| Q1 2026 | $681.1M | +8.1% |
| Q4 2025 | $925.5M | +7.6% |
| Q3 2025 | $757.8M | -0.1% |
| Q2 2025 | $585.3M | +3.7% |
| Q1 2025 | $629.8M | -4.8% |
| Q4 2024 | $859.7M | +0.2% |
CRI has the edge over GME on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.4% | +3.6 points |
| Q2 2026 | 23% | +22 points |
| Q1 2026 | 4.2% | 0 points |
| Q4 2025 | 9.2% | -0.5 points |
| Q3 2025 | 3.8% | -6.3 points |
| Q2 2025 | 0.7% | -6.3 points |
| Q1 2025 | 4.1% | -4.2 points |
| Q4 2024 | 9.7% | -6.2 points |
CRI's operating margin was 7.4% last quarter, up 3.6 points from the same quarter a year ago.
GME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $790.2M | -19% |
| Q2 2026 | $835.3M | +14% |
| Q1 2026 | $1.1B | -14% |
| Q4 2025 | $821M | -4.6% |
| Q3 2025 | $972.2M | +22% |
| Q2 2025 | $732.4M | -17% |
| Q1 2025 | $1.3B | -28% |
| Q4 2024 | $860.3M | -20% |
GME's revenue has slid since its 2022 peak: $790M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +13 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 12% | +6 points |
| Q4 2025 | 5% | +8.9 points |
| Q3 2025 | 6.8% | +9.6 points |
| Q2 2025 | -1.5% | +4.3 points |
| Q1 2025 | 6.2% | +3.1 points |
| Q4 2024 | -3.9% | -2.5 points |
GME has the edge over CRI on profitability, with a higher operating margin.
CRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$117.4M | +$26.7M |
| Q2 2026 | $190M | +688% |
| Q1 2026 | -$543K | +$58.4M |
| Q4 2025 | $247.6M | -8.6% |
| Q3 2025 | -$144.1M | -$48.4M |
| Q2 2025 | $24.1M | -77% |
| Q1 2025 | -$59M | -$21.4M |
| Q4 2024 | $270.9M | -11% |
CRI usually generates cash, though not every quarter: the latest was −$117M, but it generated $320M over the past year.
GME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60.7M | -46% |
| Q2 2026 | $332.9M | +76% |
| Q1 2026 | $187.4M | +18% |
| Q4 2025 | $107M | +435% |
| Q3 2025 | $113.3M | +73% |
| Q2 2025 | $189.6M | +$304.3M |
| Q1 2025 | $158.8M | +$177.5M |
| Q4 2024 | $20M | +80% |
GME has the edge over CRI on cash flow, with more consistent year-over-year improvement.
CRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +36.1K shares |
| 1 year | +0.5% | +192K shares |
| 3 years | -2.2% | -806K shares |
| 5 years | -18% | -7.8M shares |
| Available history | -20% | -9.1M shares |
CRI has the edge over GME on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16.7M |
| Q2 2024 | $24.8M |
| Q1 2024 | $9M |
GME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | +8.4% | +46.1M shares |
| 3 years | +94% | +288M shares |
| 5 years | +104% | +302M shares |
| Available history | +80% | +264M shares |
GME has 593M diluted shares, up 8.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | $21.8M |
| Q4 2019 | $114M |
CRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.3x | Very low |
CRI's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
GME Net Leverage
CRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 29.2 | Neutral |
CRI's weekly RSI is 49 (neutral) and its Stochastic is 29 (neutral).
GME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 68.5 | Neutral |
GME's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
CRI PE vs Consumer Cyclical Sector
| Metric | CRI | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 18x | 69% below |
| PE % | 1 | 47 | 46 pts below |
CRI has the edge over GME on valuation relative to its sector.
GME PE vs Consumer Cyclical Sector
| Metric | GME | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7.7% below |
| PE % | 15 | 47 | 32 pts below |
GME is trading at 17x earnings, in line with the Consumer Cyclical sector's median of 18x.
CRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.1 | 5.5% above |
| 20 week MA | $34.7 | 2.5% below |
| 50 week MA | $35.7 | 5% below |
| 100 week MA | $36.0 | 6% below |
| 200 week MA | $52.7 | 36% below |
CRI has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 36% below its 200-week average.
GME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.2 | 1.8% above |
| 20 week MA | $22.4 | 15% above |
| 50 week MA | $22.6 | 13% above |
| 100 week MA | $24.0 | 7% above |
| 200 week MA | $21.8 | 17% above |
GME has the edge over CRI on trend strength, trading above more of its moving averages.
CRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.1 | $95.0 | -14% |
| 2021 | $95.0 | $98.7 | +3.9% |
| 2022 | $98.7 | $73.4 | -26% |
| 2023 | $73.4 | $74.9 | +2.1% |
| 2024 | $74.9 | $54.4 | -27% |
| 2025 | $54.4 | $31.7 | -42% |
| 2026 YTD | $31.7 | $33.9 | +6.9% |
CRI has finished lower in four of the last six years. It's up 6.9% so far in 2026.
GME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.48 | $5.04 | +241% |
| 2021 | $5.04 | $38.0 | +655% |
| 2022 | $38.0 | $20.1 | -47% |
| 2023 | $20.1 | $17.5 | -13% |
| 2024 | $17.5 | $32.2 | +84% |
| 2025 | $32.2 | $21.1 | -35% |
| 2026 YTD | $21.1 | $25.6 | +21% |
GME has the edge over CRI on returns for 2026, with the stronger performance.